-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43

Benzinga·11/10/2026 14:20:42
Listen to the news
Stifel analyst Stephen Willey maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $45 to $43.